Published in Blood Weekly, June 16th, 2011
"Despite different binding sites and concentrations required for half-maximal inhibition-ranging from nanomolar for the Q site inhibitor atpenin A5 to millimolar for the succinate analog malonate-all inhibitors modulated ROS production in the same ambivalent fashion: they promoted the generation of superoxide at the Q(o) site of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2011-06-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.